President Trump just delivered a major victory for American families by securing direct deals with Big Pharma to slash costs on life-saving obesity drugs that the previous administration left unaffordable for millions of seniors.
Story Highlights
- Trump negotiated directly with Eli Lilly and Novo Nordisk to cap Medicare copays at $50 for obesity drugs like Ozempic.
- Medicare will now cover GLP-1 drugs for seniors with obesity-related health conditions for the first time.
- Medicaid programs can access $ 245-per-dose pricing, dramatically reducing monthly costs from over $1,000.
- Deal bypasses Biden-era bureaucratic negotiations, delivering immediate results through direct presidential action.
Trump Delivers Where Biden Failed
President Trump announced on November 6th that Medicare will cover weight loss medications like Ozempic, Wegovy, and Zepbound with just $50 copays for eligible seniors. This breakthrough came through direct negotiations with pharmaceutical giants Eli Lilly and Novo Nordisk, demonstrating the kind of dealmaking the previous administration couldn’t deliver. The Trump administration succeeded where Biden’s bureaucrats failed, cutting through red tape to provide immediate relief for American families struggling with obesity-related health costs.
Targeted Relief for America’s Most Vulnerable
Medicare coverage applies to seniors with a BMI over 35, those overweight with prediabetes or cardiovascular disease, and patients with advanced kidney disease, heart failure, or uncontrolled hypertension. Health Secretary Robert F. Kennedy Jr. emphasized that these targets Americans “locked into that system where they can only get ultra-processed foods.” This approach prioritizes medical necessity over bureaucratic gatekeeping, ensuring those who need these medications most can access them without financial hardship.
State Medicaid programs can now opt into $245 per dose pricing for these same medications, representing massive savings from the typical $1,000+ monthly costs. This gives states flexibility to expand access based on their populations’ needs rather than forcing top-down federal mandates. The deal operates separately from Biden’s Inflation Reduction Act negotiations, proving Trump’s direct approach delivers faster results than bureaucratic processes.
Economic Sense and Health Benefits
Trump stated this deal “will save lives and improve the health of millions and millions of Americans,” addressing the obesity crisis that affects over 40% of American adults. By making these medications accessible upfront, the deal prevents costly downstream health complications like diabetes, heart disease, and stroke that burden both families and taxpayers. This represents conservative governance at its best: targeted intervention that reduces long-term costs while expanding individual choice and access.
The agreement balances free market principles with practical results, allowing pharmaceutical companies to maintain profitability through increased volume while dramatically reducing per-patient costs. Unlike socialist healthcare schemes, this approach leverages American negotiating power and private sector innovation to deliver real solutions. Implementation begins in early 2026, giving the administration time to ensure smooth rollout without the chaos typical of government healthcare programs.
Sources:
Trump says Medicare can now cover weight loss drugs like Ozempic – Axios
